Valuation: Curis, Inc.

Market Cap 1.59M 1.42M 1.31M 1.19M 2.22M 151M 2.25M 15.74M 6.23M 78.86M 5.95M 5.82M 249M P/E 2026 *
-0.02x
P/E 2027 * -0.05x
Enterprise Value 1.59M 1.42M 1.31M 1.19M 2.22M 151M 2.25M 15.74M 6.23M 78.86M 5.95M 5.82M 249M EV / Sales 2026 *
-
EV / Sales 2027 * 0.17x
Free-Float
96.19%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Curis, Inc.

1 day-0.08%
1 week+2.41%
Current month-53.42%
1 month-52.99%
3 months-91.67%
6 months-96.64%
Current year-98.02%
1 week 0.37
Extreme 0.3655
0.42
1 month 0.32
Extreme 0.325
0.86
Current year 0.32
Extreme 0.325
24.2
1 year 0.32
Extreme 0.325
33
3 years 0.32
Extreme 0.325
349.8
5 years 0.32
Extreme 0.325
2,832
10 years 0.32
Extreme 0.325
7,440
Manager TitleAgeSince
Chief Executive Officer 59 2018-09-23
Director of Finance/CFO 54 2022-08-04
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 73 2003-10-31
Chairman 84 2017-05-15
Director/Board Member 71 2010-06-02
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26 Free

Chief Executive Officer

110,090 0.2824%
7/7/26 Free

Director

6,800 0.0174%
7/7/26 Free

Chairman

6,800 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-0.08%+2.41%-98.75%-99.52% 1.59M
+0.88%+1.18%+40.64%+74.91% 64.69B
+0.23%+7.40%+10.30%+78.18% 54.78B
+0.38%+3.13%+9.30%+100.19% 53.49B
+0.33%+5.54%+29.05%+52.15% 45.98B
-0.81%+1.09%+18.63%+125.62% 42.94B
-1.10%+1.61%+219.16%+829.58% 40.08B
-2.26%-2.06%+15.38%+45.14% 33.52B
+0.22%-4.77%+26.59%+0.55% 23.97B
+12.78%+17.58%+59.84%+47.39% 23.67B
Average +1.06%+1.49%+33.01%+125.42% 38.31B
Weighted average by Cap. +0.68%+2.59%+44.84%+151.85%

Financials

2026 *2027 *
Net sales - 9.25M 8.26M 7.63M 6.92M 12.94M 878M 13.15M 91.83M 36.36M 460M 34.71M 33.98M 1.45B
Net income -52.02M -46.45M -42.91M -38.89M -72.76M -4.94B -73.96M -516M -204M -2.59B -195M -191M -8.16B -45.23M -40.39M -37.31M -33.81M -63.26M -4.29B -64.31M -449M -178M -2.25B -170M -166M -7.09B
Net Debt - -
Projected Income Statement - Annual - Curis, Inc.
Logo Curis, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Employees
22
Date Price Change Volume
26-10-26 US$0.3908 +1.16% 42,194
26-10-23 US$0.3863 -4.59% 66,864
26-10-22 US$0.4049 +3.29% 158,201
26-10-21 US$0.3920 -1.90% 96,019
26-10-20 US$0.3996 +4.72% 217,997
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Curis, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.3863USD
Average target price
42.67USD
Spread / Average Target
+10,944.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Curis, Inc.
  1. Stock Market
  2. Stocks
  3. CRIS Stock